The FDA’s mid-November decision on Biohaven’s spinocerebellar ataxia treatment could redefine rare disease approvals and ...
Design Therapeutics, Inc. (($DSGN)) announced an update on their ongoing clinical study. Study Overview: Design Therapeutics, Inc. is conducting a ...
Limited treatment options and access to care often challenge patients with Friedreich’s ataxia. So, on Sept. 17, the ...
The National Ataxia Foundation (NAF) is an organization devoted to raising awareness, supporting families, and funding research for Ataxia, a rare and progressive neurological condition that impairs ...
(Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the poster presentation of ...
Detailed price information for Larimar Therapeutics Inc (LRMR-Q) from The Globe and Mail including charting and trades.
Please provide your email address to receive an email when new articles are posted on . Vatiquinone inhibits 15-Lipoxygenase, which regulates the pathways that Friedreich’s ataxia disrupts. PTC ...
"The findings in these abstracts are exciting for their potential to change the long-term outlook for individuals with Friedreich's ataxia," said Dr. Liana Rosenthal ... under investigation for the ...
In a small study, 80% of testicular cancer patients developed paraneoplastic neurologic syndromes before their cancer diagnosis — highlighting a need for early detection.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback